Details of the Drug Combination

General Information of Drug Combination (ID: DC7YEBC)

Drug Combination Name
Efaproxyn Tivantinib
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Efaproxyn   DMX7BM4 Tivantinib   DMNVP8Q
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 45.9
Bliss Independence Score: 40.969
Loewe Additivity Score: 1.942
LHighest Single Agent (HSA) Score: 20.437

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Efaproxyn
Disease Entry ICD 11 Status REF
Lung cancer 2C25.0 Phase 3 [2]
Efaproxyn Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Hemoglobin (HB) TTQO71U HBA_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Tivantinib
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 3 [3]
Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
Tivantinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00083304) Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
5 Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.